ロード中...
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time
We report on the immunogenicity and clinical effects in a phase I/II dose escalation trial of a DNA fusion vaccine in patients with prostate cancer. The vaccine encodes a domain (DOM) from fragment C of tetanus toxin linked to an HLA-A2-binding epitope from prostate-specific membrane antigen (PSMA),...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer-Verlag
2012
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3493666/ https://ncbi.nlm.nih.gov/pubmed/22729556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-012-1270-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|